Source link : https://www.newshealth.biz/health-news/talazoparib-combo-prolongs-survival-in-mets-prostate-cancer/
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer compared with treatment with enzalutamide alone, according to the final results of the phase 3 TALAPRO-2 study. This survival benefit occurred in both an unselected “all-comers” population and in those with homologous […]
Author : News Health
Publish date : 2025-02-14 12:05:12
Copyright for syndicated content belongs to the linked Source.